Q4 2025 earnings call: ibezapolstat rCDI trial plan, FDA one-trial shift, cash update, and Phase II data—read now.
Acurx Pharmaceuticals (ACXP) stock jumped 218% after announcing a clinical trial for ibezapolstat, which showed 96% cure rate for C. difficile infection.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing ...
On Friday, Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) reported a fourth quarter loss of -$5.32 per share for the period ended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results